A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Chung, Jooseop | - |
dc.contributor.author | Song, Hong-Suk | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Lee, Jong-Seok | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Yang, Sung Hyun | - |
dc.contributor.author | Yuh, Young Jin | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Hyun, Myung Soo | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Kim, Chul Woo | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2021-09-05T03:45:58Z | - |
dc.date.available | 2021-09-05T03:45:58Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97019 | - |
dc.description.abstract | Background. Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL). Methods. Forty-four patients with chemo-naive stage I/IINTCL were enrolled in a prospective, multicenter, phase II study and received six cycles of IMEP (ifosfamide 1.5 g/m(2) on days 1-3; methotrextate 30 mg/m(2) on days 3 and 10; etoposide 100 mg/m(2) on days 1-3; and prednisolone 60 mg/m(2) per day on days 1-5) followed by involved field radiotherapy (IFRT). Results. Overall response rates were 73% (complete remission [CR] in 11 of 41 evaluable patients [27%]) after IMEP chemotherapy and 78% (CR 18 of 27 evaluable patients [67%]) after IMEP followed by IFRT. Neutropenia and thrombocytopenia were documented in 33 patients (75%) and 7 patients (16%), respectively. Only 8 patients (18%) experienced febrile neutropenia. Three-year progression-free survival (PFS) and overall survival (OS) were 66% and 56%, respectively. High Ki-67 (>= 70%) and Ann Arbor stage II independently reduced PFS (p= 5.004) and OS (p =5.001), respectively. Conclusion. Due to the high rate of progression during IMEP chemotherapy, IFRT needs to be introduced earlier. Moreover, active chemotherapy including an L-asparaginase-based regimen should be use to reduce systemic treatment failure in stage I/II NTCL. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ALPHAMED PRESS | - |
dc.title | A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Byung Soo | - |
dc.identifier.doi | 10.1634/theoncologist.2014-0305 | - |
dc.identifier.scopusid | 2-s2.0-84908547656 | - |
dc.identifier.wosid | 000346601600006 | - |
dc.identifier.bibliographicCitation | ONCOLOGIST, v.19, no.11, pp.1129 - 1130 | - |
dc.relation.isPartOf | ONCOLOGIST | - |
dc.citation.title | ONCOLOGIST | - |
dc.citation.volume | 19 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1129 | - |
dc.citation.endPage | 1130 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.